Eli Lilly and Co. and Pfizer Inc., which are both suffering through some of the largest patent cliffs in the industry, will split any future costs and profits of an osteoarthritis drug that has stalled in clinical testing.
Testosterone replacement drugs, a $1.6 billion market for Eli Lilly and Co. and others, boosted the odds of having a heart attack, stroke or dying by 29 percent in one of the first studies weighing the therapy's cardiovascular risks.
Indianapolis-based Eli Lilly and Co., Bayer AG and Boehringer Ingelheim GmbH are among companies that may consider an offer if the Swiss drugmaker proceeds with the animal-health sale.
U.S. lawmakers, influenced by companies including Indianapolis-based Eli Lilly and Co., Cisco Systems Inc. and Qualcomm Inc., are considering the second set of patent-law changes in three years as the courts try to race ahead of Congress.
Hoosiers’ poor health, combined with an aggressive health care system and an uncompetitive health insurance sector, means Hoosiers, in spite of the fact that they earn just 86 cents for every dollar earned by the average American, are spending nearly $1.13 on health care for every dollar spent by Americans.
With a $60 million-plus investment, the university aims to take molecules from discovery to clinical trials.
Eli Lilly and Co. has been counting on torrid growth in China to help offset losses from patent expirations in other markets, but now slower growth in the Chinese economy and bribery allegations against Lilly and two other drugmakers have hampered Lilly’s growth there.
Excluding a one-time payment from a year ago, Eli Lilly and Co.’s third-quarter profit easily beat Wall Street’s expectations.
More than half of the $2.5 trillion consumers spend annually on health care in the United States flows to hospitals and doctors, with drug companies and health insurers trailing well behind.
The drugmaker has become too reliant on its remaining pipeline of drugs under development for growth as it deals with patent expirations to big sellers and drug-development setbacks, a Jefferies analyst wrote.
In a new round of predictions this month, Wall Street analysts indicated they expect Eli Lilly and Co.’s revenue to fall next year and to remain below 2013 levels until 2020.
Three former employees of Eli Lilly and Co. allegedly transferred trade secrets that Lilly values at more than $55 million to a competing Chinese drug company, according to an indictment unsealed Tuesday in federal court.
More than 60 companies plan to participate in the three-day Indy Do Day volunteer marathon, which kicks off Thursday in conjunction with Eli Lilly and Co.’s Global Day of Service.
In a series of presentations, Lilly executives stretched themselves in four directions at once to convince investors and stock analysts that the company will bend but not break next year, and then snap back stronger than ever in 2015.
Psoriasis is linked to higher rates of heart disease and diabetes, and a third of patients also develop a form of arthritis. About 125 million people worldwide have the skin condition, including 7.5 million Americans.
Eli Lilly and Co. said Thursday that meeting its sale target will be a challenge. It plans to repurchase $5 billion in shares and introduce new diabetes drugs to help navigate through patent losses. Another immediate hurdle: Obamacare.
Eli Lilly said a potential breast cancer treatment missed its main goal in a late-stage study. However, the drugmaker will seek approval to use the treatment in stomach cancer patients after ramucirumab performed better in a separate study.
Eli Lilly and Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.
Part of the funding will go to an existing study of drugs from Eli Lilly and Co. and others to see whether they can ward off the disease in people who inherited genes that predestine them to get Alzheimer’s.
With a half-dozen new products lined up for approval within two years, the fight to win the growing $22 billion U.S. diabetes market is expected to intensify.
